Patient Enquiries

Thank you for your interest in Barinthus Biotherapeutics and your enquiry about our ongoing clinical trials.

Please note that all information on ongoing or closed clinical trials run by Barinthus Biotherapeutics, including eligibility criteria and contact information are posted on the https://clinicaltrials.gov/ website.

Chronic Hepatitis B: Barinthus Biotherapeutics is conducting a Phase 2b, open-label study to evaluate the efficacy, safety, tolerability, immunogenicity and treatment regimens of VTP-300 combined with low-dose nivolumab in patients with chronic hepatitis B (CHB) virus who are virally suppressed with oral anti-viral therapies. The study is designed to confirm the HBV002 study results for ChAdOx-HBV; MVA-HBV plus nivolumab, as well as investigate additional MVA-HBV or MVA-HBV plus nivolumab administrations to CHB patients. More information and trial site contact details can be found at: https://clinicaltrials.gov/ct2/show/NCT05343481

Non-small cell lung cancer: There is an ongoing lung cancer trial run by Cancer Research UK (CRUK) with VTP-600. Information about the trial can be found at the following CRUK website: https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-a-vaccine-chemotherapy-and-an-immunotherapy-for-non-small-cell-lung-cancer

If you would like to speak with someone about this trial or other lung cancer trials, please phone the CRUK Nurses Helpline on the following number: 0808 800 4040

Prostate cancer: Barinthus Biotherapeutics is conducting a Phase 1/2 clinical trial to determine the safety, tolerability and efficacy of VTP-850 in men with biochemical recurrence after definitive local therapy for prostate cancer. More information and trial site contact details can be found at: https://clinicaltrials.gov/ct2/show/NCT05617040

Celiac disease: Barinthus Biotherapeutics is conducting a Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VTP-1000 in people with celiac disease. More information and trial site contact details can be found at: https://clinicaltrials.gov/study/NCT06310291

General information regarding Barinthus Biotherapeutics can be found on this website.

Following the implementation of GDPR legislation, Barinthus Biotherapeutics will not retain any emails which contain personal information and therefore any email communication with Barinthus Biotherapeutics will be permanently deleted from our email server.